These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32683564)

  • 1. CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
    Guvakova MA; Prabakaran I; Wu Z; Hoffman DI; Huang Y; Tchou J; Zhang PJ
    Breast Cancer Res Treat; 2020 Sep; 183(2):333-346. PubMed ID: 32683564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of ductal carcinoma in situ with invasive breast cancer in core needle biopsies for final pathologic size of intraductal elements.
    Matsumoto H; Ishii A; Nakada N; Koki A; Unesoko M; Abe N; Zaha H
    Virchows Arch; 2022 Apr; 480(4):739-748. PubMed ID: 34993592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).
    Geradts J; Groth J; Wu Y; Jin G
    Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
    Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
    Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!
    Marques LC; Marta GN; de Andrade JZ; Andrade D; de Barros ACSD; Andrade FEM
    Eur J Surg Oncol; 2019 Jul; 45(7):1152-1155. PubMed ID: 30665684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast.
    Lee SK; Yang JH; Woo SY; Lee JE; Nam SJ
    Br J Surg; 2013 Dec; 100(13):1756-63. PubMed ID: 24227361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
    Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
    Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of lesion subtypes in biopsies of ductal carcinoma in situ of the breast using biomarker ratio imaging microscopy.
    Clark AJ; Petty HR
    Sci Rep; 2016 Jun; 6():27039. PubMed ID: 27247112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nomogram for predicting underestimation of invasiveness in ductal carcinoma in situ diagnosed by preoperative needle biopsy.
    Park HS; Kim HY; Park S; Kim EK; Kim SI; Park BW
    Breast; 2013 Oct; 22(5):869-73. PubMed ID: 23601760
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhang Z; Wang H; Jin Y; Zhou J; Chu C; Tang F; Zou L; Zou Q
    Biomark Med; 2023 Jun; 17(12):553-562. PubMed ID: 37814985
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.
    Yoon HJ; Kim Y; Kim BS
    Eur Radiol; 2015 Dec; 25(12):3648-58. PubMed ID: 26063655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
    Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM
    Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
    Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
    Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
    Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.
    Rutstein LA; Johnson RR; Poller WR; Dabbs D; Groblewski J; Rakitt T; Tsung A; Kirchner T; Sumkin J; Keenan D; Soran A; Ahrendt G; Falk JS
    Breast J; 2007; 13(3):251-7. PubMed ID: 17461899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.